Literature DB >> 19676111

Evaluation of dalbavancin as chiral selector for HPLC and comparison with teicoplanin-based chiral stationary phases.

Xiaotong Zhang1, Ye Bao, Ke Huang, Kimber L Barnett-Rundlett, Daniel W Armstrong.   

Abstract

Dalbavancin is a new compound of the macrocyclic glycopeptide family. It was covalently linked to 5 microm silica particles using two different binding chemistries. Approximately 250 racemates including (a) heterocyclic compounds, (b) chiral acids, (c) chiral amines, (d) chiral alcohols, (e) chiral sulfoxides and sulfilimines, (f) amino acids and amino acid derivatives, and (g) other chiral compounds were tested on the two new chiral stationary phases (CSPs) using three different mobile phases. As dalbavancin is structurally related to teicoplanin, the same set of chiral compounds was screened on two commercially available teicoplanin CSPs for comparison. The dalbavancin CSPs were able to separate some enantiomers that were not separated by the teicoplanin CSPs and also showed improved separations for many racemates. However, there were other compounds only separated or better separated on teicoplanin CSPs. Therefore, the dalbavancin CSPs are complementary to the teicoplanin CSPs. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19676111      PMCID: PMC4309287          DOI: 10.1002/chir.20771

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  16 in total

1.  Effect of micelles and mixed micelles on efficiency and selectivity of antibiotic-based capillary electrophoretic enantioseparations.

Authors:  K L Rundlett; D W Armstrong
Journal:  Anal Chem       Date:  1995-07-01       Impact factor: 6.986

2.  Evaluation of two pairs of chiral stationary phases: effects from the length of the achiral spacers.

Authors:  Linda Thunberg; Stig Allenmark; Annika Friberg; Fredrik Ek; Torbjörn Frejd
Journal:  Chirality       Date:  2004-11       Impact factor: 2.437

3.  Direct chromatographic resolution of carnitine and O-acylcarnitine enantiomers on a teicoplanin-bonded chiral stationary phase.

Authors:  I D'Acquarica; F Gasparrini; D Misiti; C Villani; A Carotti; S Cellamare; S Muck
Journal:  J Chromatogr A       Date:  1999-10-01       Impact factor: 4.759

4.  Role of the carbohydrate moieties in chiral recognition on teicoplanin-based LC stationary phases.

Authors:  A Berthod; X Chen; J P Kullman; D W Armstrong; F Gasparrini; I D'Acquarica; C Villani; A Carotti
Journal:  Anal Chem       Date:  2000-04-15       Impact factor: 6.986

5.  Novel cinchona alkaloid carbamate C9-dimers as chiral anion-exchange type selectors for high-performance liquid chromatography.

Authors:  P Franco; M Lämmerhofer; P M Klaus; W Lindner
Journal:  J Chromatogr A       Date:  2000-02-11       Impact factor: 4.759

Review 6.  Dalbavancin: an investigational glycopeptide.

Authors:  David R P Guay
Journal:  Expert Rev Anti Infect Ther       Date:  2004-12       Impact factor: 5.091

7.  Use of a macrocyclic antibiotic, rifamycin B, and indirect detection for the resolution of racemic amino alcohols by CE.

Authors:  D W Armstrong; K Rundlett; G L Reid
Journal:  Anal Chem       Date:  1994-05-15       Impact factor: 6.986

Review 8.  Chiral recognition mechanisms with macrocyclic glycopeptide selectors.

Authors:  Alain Berthod
Journal:  Chirality       Date:  2009-01       Impact factor: 2.437

Review 9.  Dalbavancin.

Authors:  Vanessa R Anderson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Evaluation of the macrocyclic antibiotic avoparcin as a new chiral selector for HPLC.

Authors:  K H Ekborg-Ott; J P Kullman; X Wang; K Gahm; L He; D W Armstrong
Journal:  Chirality       Date:  1998       Impact factor: 2.437

View more
  1 in total

1.  Enantiomeric Separation of New Chiral Azole Compounds.

Authors:  Marziyeh E Kenari; Joshua I Putman; Ravi P Singh; Brandon B Fulton; Huy Phan; Reem K Haimour; Key Tse; Alain Berthod; Carl J Lovely; Daniel W Armstrong
Journal:  Molecules       Date:  2021-01-04       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.